Omeros Corporation (OMER), a Seattle-based commercial-stage biopharmaceutical company, has a thin sell-side coverage base. The two most current, individually verifiable analyst price targets are a $33 target from H.C. Wainwright's Brandon Folkes (Buy, October 16, 2026, lowered from $40 following a negative European CHMP opinion) and a $22 target from Cantor Fitzgerald's Olivia Brayer Saunders (Overweight, October 14, 2026, following an upgrade on a better-than-expected YARTEMLEA launch). Averaging those two gives the central $27.50 figure used here.
The $11 gap between the high and low reflects genuine disagreement about how durable YARTEMLEA's launch momentum will prove and how much the European regulatory setback on narsoplimab matters. Older targets — such as WBB Securities' $55 (May 2026) and D. Boral Capital's $36 (December 2025) — are stale and were excluded, which is why some third-party screens still show a higher average. The mean should be read as a reference point, not a guaranteed outcome. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to get a sense of how the stock has been reacting to recent news flow.
At its most recent close, OMER traded near $16.68, within a 52-week range of $6.70 to $21.24. Reaching $27.50 would require a rise of about 65%, a very large move that would also take the stock well above its prior 52-week high. The path hinges primarily on continued growth in YARTEMLEA (narsoplimab-wuug), Omeros's FDA-approved therapy for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA). Gross revenue for YARTEMLEA reached $41.8 million in the third quarter of 2026, up 29.6% sequentially, and Omeros generated positive operating cash flow of $13.3 million while holding $95.3 million in cash and short-term investments. Whether the shares can sustain a re-rating depends on converting early launch momentum into durable, profitable growth.
The stock's 52-week high near $21.24 (September 2026) acts as the first major resistance zone; a decisive close above it would be required before any move toward $27.50 becomes technically plausible. On the downside, the recent low near $16.64 provides near-term support, with the 200-day moving average near $13.77 and the 50-day average near $18.27 marking intermediate reference points. The round $20 level is also a psychological barrier. The shares trade below their 50-day average after a pullback from the September high.
Analyst price targets generally reflect a research horizon of about 12 months, though the precise horizon is rarely stated and varies by firm. Investors should watch YARTEMLEA prescription and revenue trends each quarter, any progress or appeal on the European regulatory front, FDA interactions, cash burn and cash balances, updates on the remaining 2029 notes, and any further analyst target revisions. Pipeline readouts for OMS1029 and OMS527 are also relevant longer-term catalysts.
In my own research process, I find AI Daily Buy/Sell Signals helpful for monitoring volatile names like this one. The tool applies artificial intelligence to track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on market conditions and technical behavior. It offers a data-driven layer that complements fundamental analysis, especially when coverage is thin and news can move the stock quickly.
The $27.50 target for Omeros Corporation (OMER) is the average of the two most current analyst targets ($22 to $33), not an official consensus, and it implies a very large advance of roughly 65% from a recent price near $16.68. The bull case rests on YARTEMLEA's accelerating commercial launch and improving cash generation; the bear case centers on the negative European CHMP opinion, recurring GAAP losses, dilution, and the stock's extreme volatility. With such thin coverage and a wide target range, the figure is best treated as a directional benchmark rather than a forecast. Monitor quarterly launch data, regulatory developments, and any analyst revisions for the next meaningful signal.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 28 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.586). P/E Ratio (8.812) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceutical products
Industry Biotechnology